Did doctors get the memo? study checks depakine safety alerts in saudi arabia
NCT ID NCT06714448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at whether healthcare professionals in Saudi Arabia received and understood safety materials about the epilepsy drug Depakine (sodium valproate). Researchers surveyed 455 doctors, pharmacists, and gynecologists to measure their knowledge and behavior. No treatment was given—this was purely a check on how well risk warnings are reaching prescribers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain surgery meets brain science: probing how a memory-related chemical system influences cognition
- Spotting the warning signs of drug-resistant epilepsy in children
- Could a simple conversation change how doctors treat mental illness?
- Eye scans may spot Epilepsy's silent brain damage
- Triple PET imaging could sharpen epilepsy surgery targeting
- AI-Powered portable MRI could bring epilepsy diagnosis to millions who lack access